Prova Education: Changing the Practice of Medicine

Changing the Practice of Medicine

Discover CME, tools, and guideline-focused education to
improve your knowledge - and patient outcomes.

CME/CE In-Person Event
Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice: Overcoming Clinical Inertia
May 28, 2026
Miami Beach, Florida
1.00 credit Learn more
CME/CE In-Person & Virtual Event
Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice: Overcoming Clinical Inertia
May 28, 2026
Miami Beach, Florida
1.00 credit Learn more
Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice: Overcoming Clinical Inertia
Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice: Overcoming Clinical Inertia
CME/CE Virtual Event
Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice: Overcoming Clinical Inertia
May 28, 2026
07:00 AM - 08:00 AM ET
1.00 credit Learn more
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
CME/CE Virtual Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
11:45 AM - 12:45 PM ET
Learn more
The Future of HNSCC: Aligning Teams, Transforming Care
The Future of HNSCC: Aligning Teams, Transforming Care
CME/CE
The Future of HNSCC: Aligning Teams, Transforming Care
0.25 credits
- Ravindra Uppaluri, MD, PhD
- Nancy Lee, MD, FASTRO
0.25 credits
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
MinuteCE®
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
1.00 program credit
- Christyn Edmundson, MD
1.00 program credit
MinuteCE®
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
1.00 credit 10 episodes
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 credit 10 episodes
Escalate With Intention: Stepwise, Target-Anchored Moves
Escalate With Intention: Stepwise, Target-Anchored Moves
MinuteCE®
Escalate With Intention: Stepwise, Target-Anchored Moves
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit

CME/CE

CME/CE In-Person & Virtual Event
Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice: Overcoming Clinical Inertia
May 28, 2026
Miami Beach, Florida
1.00 credit Learn more
CME/CE In-Person Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
Orlando, Florida
Learn more
The Future of HNSCC: Aligning Teams, Transforming Care
The Future of HNSCC: Aligning Teams, Transforming Care
CME/CE
The Future of HNSCC: Aligning Teams, Transforming Care
0.25 credits
- Ravindra Uppaluri, MD, PhD
- Nancy Lee, MD, FASTRO
0.25 credits
Minimal By Design: Define MSE Endpoints
Minimal By Design: Define MSE Endpoints
MinuteCE®
Minimal By Design: Define MSE Endpoints
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
MinuteCE®
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
1.00 credit 10 episodes
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 credit 10 episodes
The 2-Point Signal: Apply ≥2-Point Rule
The 2-Point Signal: Apply ≥2-Point Rule
MinuteCE®
The 2-Point Signal: Apply ≥2-Point Rule
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit

Clinical Practice

The IgG Clock: Redose Using IgG Kinetics
The IgG Clock: Redose Using IgG Kinetics
MinuteCE®
The IgG Clock: Redose Using IgG Kinetics
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
APRIL Uncovered: An Upstream Driver in IgAN
APRIL Uncovered: An Upstream Driver in IgAN
MinuteCE®
APRIL Uncovered: An Upstream Driver in IgAN
1.00 program credit
- Dana Rizk, MD
- Hong Zhang
1.00 program credit
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
MinuteCE®
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
1.00 program credit
- Richard Lafayette, MD, FACP
- Suzuki Yusuke, MD, PhD
1.00 program credit
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
MinuteCE®
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
1.00 program credit
- Richard Lafayette, MD, FACP
1.00 program credit
IgAN SOC: Strengths and Limits
IgAN SOC: Strengths and Limits
MinuteCE®
IgAN SOC: Strengths and Limits
1.00 program credit
- Dana Rizk, MD
- Suzuki Yusuke, MD, PhD
1.00 program credit
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
1.00 program credit
- Hong Zhang
1.00 program credit

Programs

Target Locked in gMG: Why T2T Matters
Target Locked in gMG: Why T2T Matters
MinuteCE®
Target Locked in gMG: Why T2T Matters
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
Mechanism-Based Targeting: Why APRIL Matters in IgAN
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®
Mechanism-Based Targeting: Why APRIL Matters in IgAN
1.00 program credit
- Suzuki Yusuke, MD, PhD
- Dana Rizk, MD
1.00 program credit
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
1.00 program credit
- Hong Zhang
1.00 program credit
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
MinuteCE®
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
1.00 program credit
- Richard Lafayette, MD, FACP
- Suzuki Yusuke, MD, PhD
1.00 program credit
Emerging Evidence: IgAN Disease-Modifying Agents
Emerging Evidence: IgAN Disease-Modifying Agents
MinuteCE®
Emerging Evidence: IgAN Disease-Modifying Agents
1.00 program credit
- Richard Lafayette, MD, FACP
- Hong Zhang
1.00 program credit
Emerging Therapies in IgAN: Who Could Benefit the Most?
Emerging Therapies in IgAN: Who Could Benefit the Most?
MinuteCE®
Emerging Therapies in IgAN: Who Could Benefit the Most?
1.00 program credit
- Richard Lafayette, MD, FACP
- Hong Zhang
1.00 program credit

Changing the Practice of Medicine

Popular

CME/CE

Clinical Practice

Programs

Title

Share on ReachMD